AI CuratorAI-generated
Research summary · AI summary · not yet reviewedHuman studyObservationalPublished in a peer-reviewed journal
MicroRNA Profile in Treatment-Naïve Adults with Primary Progressive Multiple Sclerosis
In a study of 20 treatment-naïve patients with primary progressive multiple sclerosis (PPMS) and 25 healthy controls, 26 microRNAs showed significant differences between the groups. After correction for false discovery rates, 24 of these differences remained significant.
- Tags
- #Biomarkers
- Most relevant to
- —
This plain-English summary was written by AI from a published abstract and may contain errors. It is not medical advice. Read the original study and talk to your MS team before making decisions about treatment.
- Human efficacy
- Not established from this source
- Mechanism
- Other
- Evidence strength
- Limited
- Outcome
- Not reported
Why it matters
Identifying specific microRNAs associated with PPMS could enhance our understanding of the disease's biological mechanisms and aid in the development of potential biomarkers, but further research is necessary to confirm these findings.
What this does not prove
Larger, longitudinal studies are required before diagnostic or mechanistic conclusions can be drawn.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Observational
- Participants / samples
- 45 · basis not reported
- Randomised
- Not reported
- Controlled
- Not reported
- Primary endpoint met
- Not reported
- Relevant MS type
- PPMS
- Publication date
- 2026-10-25
- Evidence reviewed
- Abstract only
- Regulatory approval
- Not reported
- Research areas
- Biomarkers
- Biological target
- Not reported
- Pathway
- Not reported
- Population
- treatment-naïve adults with PPMS
- Size of effect
- Not reported
- Secondary endpoints
- Not reported
- MRI endpoints
- Not reported
- Biomarkers
- Not reported
- Safety
- Not reported
Original sources
- Primary evidencePlasma microRNA dysregulation in treatment-naïve primary progressive multiple sclerosis: an exploratory case-control study. ↗DOI: 10.1007/s11033-026-12987-1
Supporting passages (14)
study phaseMETHODS AND RESULTS: In this exploratory case-control study, plasma samples from 20 newly diagnosed, treatment-naïve patients with PPMS and 25 healthy controls with broadly comparable age and sex distributions were assayed for 84 neurologically relevant miRNAs using high-throughput real-time quantitative polymerase chain reaction on the BioMark HD platform.
subjectsMETHODS AND RESULTS: In this exploratory case-control study, plasma samples from 20 newly diagnosed, treatment-naïve patients with PPMS and 25 healthy controls with broadly comparable age and sex distributions were assayed for 84 neurologically relevant miRNAs using high-throughput real-time quantitative polymerase chain reaction on the BioMark HD platform.
sample sizeMETHODS AND RESULTS: In this exploratory case-control study, plasma samples from 20 newly diagnosed, treatment-naïve patients with PPMS and 25 healthy controls with broadly comparable age and sex distributions were assayed for 84 neurologically relevant miRNAs using high-throughput real-time quantitative polymerase chain reaction on the BioMark HD platform.
relevant ms typesBACKGROUND: Primary progressive multiple sclerosis (PPMS) is a disabling phenotype marked by gradual neurological worsening from disease onset and limited biomarker availability.
publication date2026-10-25
comparatorhealthy controls
findingsTwenty-six miRNAs exhibited nominal between-group differences, of which 24 remained significant after Benjamini-Hochberg false discovery rate correction at q < 0.05.
limitationsLarger, longitudinal studies are required before diagnostic or mechanistic conclusions can be drawn.
mechanismsIntegrated analyses associated the biologically prioritized target set with miRNA biogenesis, stress-responsive signaling, inflammatory pathways, hypoxia/angiogenesis, and cell-cycle regulation.
populationMETHODS AND RESULTS: In this exploratory case-control study, plasma samples from 20 newly diagnosed, treatment-naïve patients with PPMS and 25 healthy controls with broadly comparable age and sex distributions were assayed for 84 neurologically relevant miRNAs using high-throughput real-time quantitative polymerase chain reaction on the BioMark HD platform.
peer reviewedPublication types: Journal Article
subjectsMeSH terms: Humans; Multiple Sclerosis, Chronic Progressive; Case-Control Studies; Female; MicroRNAs; Male; Biomarkers; Middle Aged; Gene Expression Profiling; Adult; Gene Expression Regulation; Circulating MicroRNA
study designMeSH terms: Humans; Multiple Sclerosis, Chronic Progressive; Case-Control Studies; Female; MicroRNAs; Male; Biomarkers; Middle Aged; Gene Expression Profiling; Adult; Gene Expression Regulation; Circulating MicroRNA
research categoriesMeSH terms: Humans; Multiple Sclerosis, Chronic Progressive; Case-Control Studies; Female; MicroRNAs; Male; Biomarkers; Middle Aged; Gene Expression Profiling; Adult; Gene Expression Regulation; Circulating MicroRNA
AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.